These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23018302)

  • 1. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy.
    Casella AM; Berbel RF; Bressanim GL; Malaguido MR; Cardillo JA
    Clinics (Sao Paulo); 2012 Sep; 67(9):1047-52. PubMed ID: 23018302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.
    Zavoloka O; Bezditko P; Lahorzhevska I; Zubkova D; Ilyina Y
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1737-42. PubMed ID: 26979068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy.
    Rahbani-Nobar MB; Javadzadeh A; Ghojazadeh L; Rafeey M; Ghorbanihaghjo A
    Mol Vis; 2011 Jan; 17():99-103. PubMed ID: 21245962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for central serous chorioretinopathy: a network meta-analysis.
    Salehi M; Wenick AS; Law HA; Evans JR; Gehlbach P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011841. PubMed ID: 26691378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choroidal Thickness of Helicobacter-Positive Patients without Central Serous Chorioretinopathy.
    Horozoglu F; Sever O; Celik E; Mete R; Sahin E
    Curr Eye Res; 2018 Feb; 43(2):262-265. PubMed ID: 29135305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).
    Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Guo J; Tang W; Liu W; Chang Q; Xu G
    Retina; 2021 Jan; 41(1):199-207. PubMed ID: 32251241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F
    Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Mohabati D; Hoyng CB; Yzer S; Boon CJF
    Retina; 2020 Sep; 40(9):1742-1750. PubMed ID: 31815880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Grzybowski A
    Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2299-2306. PubMed ID: 28831603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
    Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
    Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SEROUS MACULAR DETACHMENT IN BEST DISEASE: A Masquerade Syndrome.
    Zatreanu L; Freund KB; Leong BCS; Yu HG; Teke MY; Yzer S; Sadda SR; Sarraf D
    Retina; 2020 Aug; 40(8):1456-1470. PubMed ID: 31613838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.